中国医学创新
中國醫學創新
중국의학창신
MEDICAL INNOVATION OF CHINA
2013年
34期
45-47
,共3页
晏勇%余霞萍%陈希林%刘长山%林应花
晏勇%餘霞萍%陳希林%劉長山%林應花
안용%여하평%진희림%류장산%림응화
慢性特发性荨麻疹%胸腺五肽%治疗
慢性特髮性蕁痳疹%胸腺五肽%治療
만성특발성담마진%흉선오태%치료
Chronic idiopathic urticaria%Thymopentin-5%Treatment
目的：探讨胸腺五肽联合地氯雷他定治疗慢性特发性荨麻疹的临床疗效。方法：治疗慢性特发性荨麻疹患者180例，按照随机数字表法将其分为治疗组和对照组各90例。治疗组：口服地氯雷他定分散片5 mg，1次/d，同时胸腺五肽针1 mg加入0.9%氯化钠注射液250 mL，静脉滴注，1次/d；对照组：口服地氯雷他定片5 mg，1次/d。两组均连续用药4周后，随访观察12周，评定疗效并记录皮损变化和不良反应。结果：治疗组痊愈率为95.6%，总有效率为97.8%，对照组痊愈率为90%，总有效率为95.6%。两组短期症状控制效果都非常有效，差异无统计学意义（P>0.05）。两组痊愈患者复发情况观察结果显示，治疗组停药超过12周未复发（优等）病例52例（60.5%），对照组11例（13.6%）；治疗组停药后4周以内复发（差等）病例9例（10.4%），对照组38例（46.9%），两组比较差异均有统计学意义（P<0.01）。研究结果显示远期疗效治疗组明显优于对照组，治疗组能有效减少治疗后复发率。结论：胸腺五肽联合地氯雷他定治疗慢性特发性荨麻疹疗效明显，能有效控制风团和瘙痒，副作用小，复发率低，远期疗效明显高于单用地氯雷他定治疗。
目的：探討胸腺五肽聯閤地氯雷他定治療慢性特髮性蕁痳疹的臨床療效。方法：治療慢性特髮性蕁痳疹患者180例，按照隨機數字錶法將其分為治療組和對照組各90例。治療組：口服地氯雷他定分散片5 mg，1次/d，同時胸腺五肽針1 mg加入0.9%氯化鈉註射液250 mL，靜脈滴註，1次/d；對照組：口服地氯雷他定片5 mg，1次/d。兩組均連續用藥4週後，隨訪觀察12週，評定療效併記錄皮損變化和不良反應。結果：治療組痊愈率為95.6%，總有效率為97.8%，對照組痊愈率為90%，總有效率為95.6%。兩組短期癥狀控製效果都非常有效，差異無統計學意義（P>0.05）。兩組痊愈患者複髮情況觀察結果顯示，治療組停藥超過12週未複髮（優等）病例52例（60.5%），對照組11例（13.6%）；治療組停藥後4週以內複髮（差等）病例9例（10.4%），對照組38例（46.9%），兩組比較差異均有統計學意義（P<0.01）。研究結果顯示遠期療效治療組明顯優于對照組，治療組能有效減少治療後複髮率。結論：胸腺五肽聯閤地氯雷他定治療慢性特髮性蕁痳疹療效明顯，能有效控製風糰和瘙癢，副作用小，複髮率低，遠期療效明顯高于單用地氯雷他定治療。
목적：탐토흉선오태연합지록뢰타정치료만성특발성담마진적림상료효。방법：치료만성특발성담마진환자180례，안조수궤수자표법장기분위치료조화대조조각90례。치료조：구복지록뢰타정분산편5 mg，1차/d，동시흉선오태침1 mg가입0.9%록화납주사액250 mL，정맥적주，1차/d；대조조：구복지록뢰타정편5 mg，1차/d。량조균련속용약4주후，수방관찰12주，평정료효병기록피손변화화불량반응。결과：치료조전유솔위95.6%，총유효솔위97.8%，대조조전유솔위90%，총유효솔위95.6%。량조단기증상공제효과도비상유효，차이무통계학의의（P>0.05）。량조전유환자복발정황관찰결과현시，치료조정약초과12주미복발（우등）병례52례（60.5%），대조조11례（13.6%）；치료조정약후4주이내복발（차등）병례9례（10.4%），대조조38례（46.9%），량조비교차이균유통계학의의（P<0.01）。연구결과현시원기료효치료조명현우우대조조，치료조능유효감소치료후복발솔。결론：흉선오태연합지록뢰타정치료만성특발성담마진료효명현，능유효공제풍단화소양，부작용소，복발솔저，원기료효명현고우단용지록뢰타정치료。
Objective:To investigate the clinical efficacy of Thymopentin-5 combined with desloratadine in treatment of chronic idiopathic urticaria.Method:The treatment of chronic idiopathic urticaria patients 180 cases,randomly divided into the treatment group and the control group,90 cases in each group.Treatment group:Oral desloratadine dispersible tablets 5 mg,qd,at the same time the Thymopentin-5 1 mg added 0.9%sodium chloride injection 250 mL,intravenous drip,qd;Control group:Oral desloratadine tablets 5 mg,qd. The two groups were treated for 4 weeks,followed up for 12 weeks,evaluated and recorded the efficacy and adverse reaction in skin lesions.Result:The cure rate of the treatment group was 95.6%,the total effective rate was 97.8%,the cure rate of the control group was 90.0%,the total effective rate was 95.6%,and the difference of two indicates above between the two groups were no statistically significant(P>0.05). The two group of patients relapse were observed. The results showed,the treatment group was more than 12 weeks in withdrawal recurrence(top)of 52 cases(60.5%),11 cases in the control group(13.6%),the treatment group 4 weeks after withdrawal recurrence within 9(low)cases(10.4%),38 cases in the control group(46.9%),and the difference of two indicates above between the two groups were no statistically significant(P<0.01).Conclusion:Thymopentin-5 combined with desloratadine in treatment of chronic idiopathic urticaria obvious curative effect,can effectively control the nettle rash and itching,little side effect,low recurrence rate,long-term effect is obviously higher than that of single desloratadine therapy.
